Marpam Pharma LLC
Oakdale, MN
- UEI
- FJN8ZEF912K7
- CAGE
- 8F2R2
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 6553 2nd St N, Oakdale, MN 55128, USA
- Website
- marpampharma.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $14,131,077 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a cost-effective in-vivo therapy for durable remission of HIV | Interior Business Center (DO) | $14,131,077 |
Grant awards
Similar vendors
About the company
Marpam Pharma LLC is a woman-owned small business and limited liability company registered in SAM.gov, specializing in innovative biotechnology research focused on developing advanced therapies for Human Immunodeficiency Virus (HIV). Based in Oakdale, Minnesota, the company concentrates on developing chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies designed to target viral reservoirs and potentially provide durable remission from HIV. The company is classified as a self-certified small disadvantaged business and for-profit organization, with a current SAM.gov registration valid through March 20, 2026.
Through its federal contract awards, Marpam Pharma LLC has secured a significant $33,642,298 Other Transaction Agreement with the National Institutes of Health (NIH) to develop a cost-effective in-vivo therapy for achieving durable HIV remission. The contract, awarded on September 25, 2025, has a performance period extending through September 24, 2031 and is not set aside for any specific business category. The contract supports the company's ongoing research into innovative HIV treatment approaches, specifically focusing on developing therapeutic strategies that could potentially eliminate the need for continuous antiretroviral therapies.
Marpam Pharma LLC has received multiple federal grants from the National Institute of Allergy and Infectious Diseases (NIAID) to support its groundbreaking HIV research. These project grants, awarded in July 2022, December 2022, and March 2024, focus on developing advanced CAR-T cell therapies targeting viral reservoirs in lymphoid B cell follicles. The research aims to create a one-time treatment for HIV that can achieve durable remission, particularly for patients who are not effectively managed by current antiretroviral therapies. The grants support proof-of-concept studies for in-vivo produced CAR-T cells, exploring innovative approaches such as using the CXCR5 chemokine receptor as a homing mechanism to direct anti-HIV killer T-cells into hidden viral reservoirs, with potential applications for patients who are ART-naive, non-compliant, or not successfully suppressed by existing treatments.
Quick answers
Is Marpam Pharma LLC registered in SAM.gov?
Yes. Marpam Pharma LLC's SAM.gov registration is active through March 23, 2027.
How much has Marpam Pharma LLC received in federal contracts?
Federal contracts obligated $14,131,077 to Marpam Pharma LLC in fiscal year 2025.
How does Marpam Pharma LLC rank among federal contractors?
Marpam Pharma LLC ranked #22 in PSC AN13 and #59 in PSC AN in FY2025.
What is Marpam Pharma LLC's most recent federal award?
Marpam Pharma LLC's most recent federal contract award is Development of a cost-effective in-vivo therapy for durable remission of HIV (140D042590003), from Interior Business Center (DO), on September 25, 2025.
On GovTribe
See Marpam Pharma LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors